GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » EV-to-FCF

Takara Bio (TSE:4974) EV-to-FCF : -7.79 (As of Jun. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Takara Bio's Enterprise Value is 円86,931 Mil. Takara Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was 円-11,161 Mil. Therefore, Takara Bio's EV-to-FCF for today is -7.79.

The historical rank and industry rank for Takara Bio's EV-to-FCF or its related term are showing as below:

TSE:4974' s EV-to-FCF Range Over the Past 10 Years
Min: -1046.87   Med: 16.46   Max: 2282.7
Current: -7.73

During the past 13 years, the highest EV-to-FCF of Takara Bio was 2282.70. The lowest was -1046.87. And the median was 16.46.

TSE:4974's EV-to-FCF is ranked worse than
100% of 383 companies
in the Biotechnology industry
Industry Median: 7.86 vs TSE:4974: -7.73

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-15), Takara Bio's stock price is 円1008.00. Takara Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was 円12.289. Therefore, Takara Bio's PE Ratio for today is 82.02.


Takara Bio EV-to-FCF Historical Data

The historical data trend for Takara Bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio EV-to-FCF Chart

Takara Bio Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 109.14 65.25 -44.55 5.10 -7.46

Takara Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 5.62 7.93 11.76 -7.46

Competitive Comparison of Takara Bio's EV-to-FCF

For the Biotechnology subindustry, Takara Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Takara Bio's EV-to-FCF falls into.



Takara Bio EV-to-FCF Calculation

Takara Bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=86930.925/-11161
=-7.79

Takara Bio's current Enterprise Value is 円86,931 Mil.
Takara Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-11,161 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takara Bio  (TSE:4974) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Takara Bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1008.00/12.289
=82.02

Takara Bio's share price for today is 円1008.00.
Takara Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円12.289.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Takara Bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Takara Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines